Diffuse Cutaneous Systemic Sclerosis
Conditions
Brief summary
To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in Diffuse Systemic Sclerosis (ACR CRISS) at Week 52
Interventions
DRUGMT-7117
MT-7117
DRUGPlacebo
Placebo
Sponsors
Tanabe Pharma America, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Additional screening criteria check may apply for qualification. Inclusion Criteria: * Subjects who meet all the following criteria will be considered eligible to participate in the study: 1. Must provide signed and dated informed consent form (ICF) to participate in the study. Subjects must be able to (in the judgment of the Investigator) understand the nature of the study and all risks involved with participation in the study. Subjects must be willing to cooperate and comply with all protocol restrictions and procedures including study visits. 2. Male or female age ≥ 18 years at screening with documented diagnosis of systemic sclerosis (SSc), as defined using the 2013 ACR/European League Against Rheumatism (EULAR) criteria. 3. Has diffuse cutaneous form of SSc according to Leroy and Medsger's criteria. 4. Disease duration ≤ 5 years from the first non-Raynaud's phenomenon manifestation. 5. Has an mRSS of 15 to 45 units at screening and have clinical skin involvement proximal and distal to the elbows, knees, or both or any truncal involvement, with or without face involvement. 6. If disease duration is \> 24 months defined as time from the first non Raynaud phenomenon manifestation, subject must fulfill at least 1 of the criteria listed below that are indicatives of active disease at screening: 1. A documentation of new skin involvement that occurred within the past 9 months, or 2. Increase in mRSS ≥ 3 units within the past 9 months, or 3. Presence of TFRs or, 4. C- reactive protein (CRP) ≥ 6 mg/L, or 5. Erythrocyte sedimentation rate ≥ 28 mm/hr, or 6. Platelet count ≥ 330 x 10\^9/L (330,000/microliter). NOTE: Investigator should exclude all other acute intercurrent illness if subjects fulfilling laboratory criteria (d, e, f) only. 7. Willing to follow restrictions regarding concomitant medications that are described. 8. Female subjects who are non-lactating and have a negative urine pregnancy test at baseline visit prior to receiving the first dose of study drug. 9. Female subjects of childbearing potential and male subjects with partner of child-bearing potential currently using/willing to use 2 effective methods of contraception including barrier method as described.
Exclusion criteria
\- Subjects will be excluded from the study if any of the following criteria apply: 1. Has a history or presence of rheumatic autoimmune diseases other than dcSSc unless the dominant features of the disease are dcSSc, as determined by the Investigator. 2. Has a pulmonary disease with FVC ≤ 50% of predicted at time of screening. 3. Has a diagnosis of clinically significant resting pulmonary hypertension (if exceeding estimated right ventricular systolic pressure of \> 40 mmHg estimated by transthoracic echocardiography \[unless the right heart catheterization is normal within the last 6 months\] or mean pulmonary artery pressure \> 30 mmHg as measured by right heart catheterization) and requires treatment with more than one oral medication. 4. Has a cardiac abnormality such as left ventricular failure with ejection fraction \< 45%, significant arrhythmia, congestive heart failure (New York Heart Association Class II-IV), unstable angina, uncontrolled hypertension, or symptomatic pericardial effusion at screening. 5. Has a history of myocardial infarction in the last 26 weeks prior to screening. 6. Has a history of renal crisis within the past 52 weeks prior to screening. 7. Has a documented history of chronic kidney disease (stage 4-5, an estimated glomerular filtration rate \[eGFR\] \< 30 mL/min at screening). 8. Presence or history of hepatobiliary disease at screening, determined as clinically significant by the Investigator after the discussion with the Sponsor Medical Monitor. 9. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≥ 2.0 × upper limit of normal (ULN), or total bilirubin \> 1.5 × ULN at screening. 10. Has a history or presence of clinically significant disease not related to SSc \[neurologic, renal, endocrinal, gastrointestinal cardiovascular, hepatic, dermatologic, hematological, musculoskeletal, genitourinary, thromboembolic, advanced arteriosclerosis, hyperthyroidism, moderate to severe hypertension, immunologic disease, pulmonary (e.g., uncontrolled asthma, emphysema, chronic obstructive pulmonary disease) or any other disorder\] as determined by the Investigator at screening. Conditions deemed not-clinically significant according to the Investigator's discretion are acceptable. 11. Has a history or presence of psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation and/or safety of the subject. 12. Has any clinically significant disease or laboratory abnormality judged to be clinically significant by the Investigator and which may interfere with the study evaluation and/or safety of the subject at screening. Laboratory abnormalities include but not limited to any of the followings: Hemoglobin \< 9 g/dL; WBC \< 3,000/mm3 (\< 3 x 10\^9/L); platelets \< 100,000/mm3 (\<100 x 10\^9/L). 13. Has a history of positive hepatitis B surface antigen, hepatitis C antibody, except for documented cure for the hepatitis B virus (HBV), defined as sustained, undetectable HBsAg and HBV DNA in serum and adequately treated hepatitis C virus (HCV) with documentation of sustained virologic response defined as undetectable HCV RNA at least 12 weeks after the end of treatment. 14. Has a history of positive human immunodeficiency virus (HIV) 15. Has a history of melanoma, familial melanoma (defined as having 2 or more first-degree relatives, such as parent, sibling, and/or child), or presence of melanoma and/or lesions suspicious for melanoma at screening. 16. Has a presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin lesions. Any suspicious lesions or nevi (Melanocytic Lesions) will be evaluated. If the suspicious lesion or nevi (Melanocytic Lesions) cannot be resolved through biopsy or excision, the subject will be excluded from the study. 17. Has history of any other malignancy(ies) in the last 5 years with the exception of cervical carcinoma in situ. 18. Has a history or planning to receive cell-depleting therapy or bone marrow transplantation during study treatment period. 19. Has a history of ultraviolet (UV) phototherapy within 6 weeks prior to screening or planning to receive UV phototherapy during study treatment period. 20. Treatment of SSc disease with 1. Cyclophosphamide, rituximab, or cyclosporine received within 26 weeks prior to screening. 2. Small molecules such as JAK inhibitors (e.g., tofacitinib) received within 12 weeks prior to screening. 3. Pirfenidone received within 12 weeks prior to screening. 4. Infliximab, certolizumab, golimumab, adalimumab, abatacept, tocilizumab within 10 weeks prior to screening. 5. Etanercept within 4 weeks prior to screening. 6. Oral, intravenous, or intramuscular corticosteroids (prednisone \> 10 mg/day or equivalent) received within 30 days prior to screening 7. Nintedanib within 12 weeks prior to screening. 8. More than 1 of the immunosuppressant therapy listed below as concomitant therapy with study drug, has changed one of the medication below within 12 weeks prior to screening, or not on a stable dose of the same medication for at least 12 weeks prior to screening. * i. Mycophenolate (up to 3 g/day), or * ii. Mycophenolic acid (up to 2.14 g/day), or * iii. Methotrexate (up to 25 mg/Week), or * iv. Leflunomide (up to 20 mg/day), or * v. Azathioprine (up to 3 mg/kg/day). 21. Treatment with afamelanotide or other MC1R agonist within 12 weeks before screening (Visit 1). 22. Treatment with any drugs or supplements which, in the opinion of the Investigator, may interfere with the objectives of the study or safety of the subject. 23. Has previously exposed to MT 7117 (this does not include placebo treated subjects). 24. Has previously treated with any investigational agent within 12 weeks prior to screening OR 5 half-lives of the investigational product (whichever is longer). 25. Female subjects who are pregnant, lactating, or intending to become pregnant during the study. 26. Has a positive autoantibody status of anti-centromere antibody.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The ACR CRISS Composite Score (0-1) at Week 52 | Week 52 | The comparison between MT-7117 treatment group and placebo group will be performed. The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52 | 52 weeks | To evaluate the efficacy of MT 7117 treatment for up to 52 weeks using the Health Assessment Questionnaire Disability Index (HAQ DI). The Health Assessment Questionnaire Disability Index (HAQ-DI) is a self-administered instrument consists of 20 questions referring to eight component sets consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored on a 4-point scale from 0 to 3: 0 = Without any difficulty; 1 = With some difficulty; 2 = With much difficulty; 3 = Unable to do. Overall score was computed as the sum of component set scores and divided by the number of component sets answered. This outcome measure represents the change in mean score from baseline. A negative change from baseline indicates improvement. |
| Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52 | 52 weeks | To evaluate the efficacy of MT-7117 treatment for up to 52 weeks on pulmonary function as measured by percent predicted forced vital capacity (%pFVC) |
| Change in Patient Global Assessment From Baseline up to Week 52 | 52 weeks | To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the Patient Global Assessment |
| ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52 | 52 weeks | To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using CRISS Score. Subjects with CRISS score is \>=0.60 are considered improved, while subjects with CRISS score \< 0.60 are considered not improved. |
| Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52 | 52 weeks | To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the modified Rodnan Skin Score (mRSS). mRSS evaluates a subject's skin thickness which will be assessed by palpation and rated using an mRSS that ranges from 0 (normal) to 3 (severe skin thickening) across 17 different body sites. The total score is the sum of the individual skin scores from all of these sites and ranges from 0 to 51 units. |
| ACR CRISS Score up to Week 39 | 39 weeks | To evaluate the efficacy of MT 7117 treatment for up to 39 weeks using the ACR CRISS Score. The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement. |
| Change in Physician Global Assessment From Baseline up to Week 52 | 52 weeks | To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the Physician Global Assessment. The Physician Global Assessment is used to assess the physician's rating of overall health of the subject. Physicians rate the perceived health of the subject on an 11-point scale from 0 (excellent) to 10 (extremely poor). |
Countries
Belgium, Canada, Germany, Italy, Poland, Spain, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| MT-7117 Oral tablet of MT-7117 once a day. | 38 |
| Placebo Oral tablet of placebo once a day. | 38 |
| Total | 76 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 8 | 0 |
| Overall Study | Lost to Follow-up | 1 | 0 |
| Overall Study | Other therapy needed | 0 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 1 |
Baseline characteristics
| Characteristic | MT-7117 | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 49.2 years STANDARD_DEVIATION 12.5 | 54.2 years STANDARD_DEVIATION 12.4 | 51.7 years STANDARD_DEVIATION 12.6 |
| Race/Ethnicity, Customized Hispanic or Latino | 7 Participants | 7 Participants | 14 Participants |
| Race/Ethnicity, Customized Non-hispanic or Latino | 31 Participants | 29 Participants | 60 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 2 Participants | 2 Participants |
| Sex: Female, Male Female | 26 Participants | 30 Participants | 56 Participants |
| Sex: Female, Male Male | 12 Participants | 8 Participants | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 38 | 0 / 38 |
| other Total, other adverse events | 35 / 38 | 28 / 38 |
| serious Total, serious adverse events | 4 / 38 | 2 / 38 |
Outcome results
Primary
The ACR CRISS Composite Score (0-1) at Week 52
The comparison between MT-7117 treatment group and placebo group will be performed. The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement.
Time frame: Week 52
Population: Reason of discrepancy between Number analyzed and Overall Number of Participants Analyzed: The analysis was performed only in patients who have data at week 52.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MT-7117 | The ACR CRISS Composite Score (0-1) at Week 52 | 0.8537 scores on ascale |
| Placebo | The ACR CRISS Composite Score (0-1) at Week 52 | 0.8502 scores on ascale |
Secondary
ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52
To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using CRISS Score. Subjects with CRISS score is \>=0.60 are considered improved, while subjects with CRISS score \< 0.60 are considered not improved.
Time frame: 52 weeks
Population: Reason of discrepancy between Number analyzed of each row and Overall Number of Participants Analyzed: The analysis was performed only in patients who have data at each week.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| MT-7117 | ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52 | Week 16 | 10 Participants |
| MT-7117 | ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52 | Week 26 | 10 Participants |
| MT-7117 | ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52 | Week 39 | 11 Participants |
| MT-7117 | ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52 | Week 52 | 14 Participants |
| Placebo | ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52 | Week 52 | 18 Participants |
| Placebo | ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52 | Week 16 | 8 Participants |
| Placebo | ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52 | Week 39 | 15 Participants |
| Placebo | ACR CRISS Score Responder (CRISS>=0.6) From Baseline up to Week 52 | Week 26 | 18 Participants |
Secondary
ACR CRISS Score up to Week 39
To evaluate the efficacy of MT 7117 treatment for up to 39 weeks using the ACR CRISS Score. The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement.
Time frame: 39 weeks
Population: Reason of discrepancy between Number analyzed of each row and Overall Number of Participants Analyzed: The analysis was performed only in patients who have data at each week.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| MT-7117 | ACR CRISS Score up to Week 39 | Week 16 | 0.0349 scores on ascale |
| MT-7117 | ACR CRISS Score up to Week 39 | Week 26 | 0.2626 scores on ascale |
| MT-7117 | ACR CRISS Score up to Week 39 | Week 39 | 0.3890 scores on ascale |
| Placebo | ACR CRISS Score up to Week 39 | Week 16 | 0.1236 scores on ascale |
| Placebo | ACR CRISS Score up to Week 39 | Week 26 | 0.6232 scores on ascale |
| Placebo | ACR CRISS Score up to Week 39 | Week 39 | 0.5289 scores on ascale |
Secondary
Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52
To evaluate the efficacy of MT 7117 treatment for up to 52 weeks using the Health Assessment Questionnaire Disability Index (HAQ DI). The Health Assessment Questionnaire Disability Index (HAQ-DI) is a self-administered instrument consists of 20 questions referring to eight component sets consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored on a 4-point scale from 0 to 3: 0 = Without any difficulty; 1 = With some difficulty; 2 = With much difficulty; 3 = Unable to do. Overall score was computed as the sum of component set scores and divided by the number of component sets answered. This outcome measure represents the change in mean score from baseline. A negative change from baseline indicates improvement.
Time frame: 52 weeks
Population: The analysis was performed only in patients who have data at each week.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MT-7117 | Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52 | Change from baseline (BL) at Week 16 | -0.1439 score on a scale | Standard Deviation 0.3803 |
| MT-7117 | Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52 | Change from BL at Week 26 | -0.0847 score on a scale | Standard Deviation 0.336 |
| MT-7117 | Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52 | Change from BL at Week 39 | -0.0927 score on a scale | Standard Deviation 0.3178 |
| MT-7117 | Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52 | Change from BL at Week 52 | -0.1111 score on a scale | Standard Deviation 0.4265 |
| Placebo | Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52 | Change from BL at Week 52 | -0.0208 score on a scale | Standard Deviation 0.5102 |
| Placebo | Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52 | Change from baseline (BL) at Week 16 | -0.0395 score on a scale | Standard Deviation 0.39 |
| Placebo | Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52 | Change from BL at Week 39 | -0.0439 score on a scale | Standard Deviation 0.5147 |
| Placebo | Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline up to Week 52 | Change from BL at Week 26 | -0.0691 score on a scale | Standard Deviation 0.4481 |
Secondary
Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52
To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the modified Rodnan Skin Score (mRSS). mRSS evaluates a subject's skin thickness which will be assessed by palpation and rated using an mRSS that ranges from 0 (normal) to 3 (severe skin thickening) across 17 different body sites. The total score is the sum of the individual skin scores from all of these sites and ranges from 0 to 51 units.
Time frame: 52 weeks
Population: Reason of discrepancy between Number analyzed of each row and Overall Number of Participants Analyzed: The analysis was performed only in patients who have data at each week.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MT-7117 | Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52 | Change from BL at Week 16 | -3.2 score on a scale | Standard Deviation 4.7 |
| MT-7117 | Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52 | Change from BL at Week 26 | -4.9 score on a scale | Standard Deviation 5.5 |
| MT-7117 | Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52 | Change from BL at Week 39 | -6.4 score on a scale | Standard Deviation 7 |
| MT-7117 | Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52 | Change from BL at Week 52 | -6.6 score on a scale | Standard Deviation 8.2 |
| Placebo | Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52 | Change from BL at Week 52 | -6.5 score on a scale | Standard Deviation 7.9 |
| Placebo | Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52 | Change from BL at Week 16 | -3.6 score on a scale | Standard Deviation 3.9 |
| Placebo | Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52 | Change from BL at Week 39 | -6.2 score on a scale | Standard Deviation 7.5 |
| Placebo | Change in Modified Rodnan Skin Score (mRSS) From Baseline From Baseline up to Week 52 | Change from BL at Week 26 | -5.3 score on a scale | Standard Deviation 6.9 |
Secondary
Change in Patient Global Assessment From Baseline up to Week 52
To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the Patient Global Assessment
Time frame: 52 weeks
Population: Reason of discrepancy between Number analyzed of each row and Overall Number of Participants Analyzed: The analysis was performed only in patients who have data at each week.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MT-7117 | Change in Patient Global Assessment From Baseline up to Week 52 | Change from BL at Week 16 | -0.8 score on a scale | Standard Deviation 1.8 |
| MT-7117 | Change in Patient Global Assessment From Baseline up to Week 52 | Change from BL at Week 26 | 0.0 score on a scale | Standard Deviation 2.5 |
| MT-7117 | Change in Patient Global Assessment From Baseline up to Week 52 | Change from BL at Week 39 | -0.7 score on a scale | Standard Deviation 2.2 |
| MT-7117 | Change in Patient Global Assessment From Baseline up to Week 52 | Change from BL at Week 52 | -0.5 score on a scale | Standard Deviation 2.3 |
| Placebo | Change in Patient Global Assessment From Baseline up to Week 52 | Change from BL at Week 52 | -0.3 score on a scale | Standard Deviation 2.5 |
| Placebo | Change in Patient Global Assessment From Baseline up to Week 52 | Change from BL at Week 16 | -0.3 score on a scale | Standard Deviation 1.9 |
| Placebo | Change in Patient Global Assessment From Baseline up to Week 52 | Change from BL at Week 39 | -0.5 score on a scale | Standard Deviation 2.3 |
| Placebo | Change in Patient Global Assessment From Baseline up to Week 52 | Change from BL at Week 26 | -0.4 score on a scale | Standard Deviation 2.6 |
Secondary
Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52
To evaluate the efficacy of MT-7117 treatment for up to 52 weeks on pulmonary function as measured by percent predicted forced vital capacity (%pFVC)
Time frame: 52 weeks
Population: Reason of discrepancy between Number analyzed of each row and Overall Number of Participants Analyzed: The analysis was performed only in patients who have data at each week.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MT-7117 | Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52 | Change from BL at Week 16 | 0.754 %pFVC | Standard Deviation 4.938 |
| MT-7117 | Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52 | Change from BL at Week 26 | 0.904 %pFVC | Standard Deviation 5.669 |
| MT-7117 | Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52 | Change from BL at Week 39 | -1.201 %pFVC | Standard Deviation 6.293 |
| MT-7117 | Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52 | Change from BL at Week 52 | 0.048 %pFVC | Standard Deviation 6.917 |
| Placebo | Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52 | Change from BL at Week 52 | -2.906 %pFVC | Standard Deviation 5.101 |
| Placebo | Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52 | Change from BL at Week 16 | -1.058 %pFVC | Standard Deviation 5.749 |
| Placebo | Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52 | Change from BL at Week 39 | -1.457 %pFVC | Standard Deviation 5.6 |
| Placebo | Change in Percent Predicted Forced Vital Capacity (%pFVC) From Baseline up to Week 52 | Change from BL at Week 26 | -0.691 %pFVC | Standard Deviation 5.847 |
Secondary
Change in Physician Global Assessment From Baseline up to Week 52
To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the Physician Global Assessment. The Physician Global Assessment is used to assess the physician's rating of overall health of the subject. Physicians rate the perceived health of the subject on an 11-point scale from 0 (excellent) to 10 (extremely poor).
Time frame: 52 weeks
Population: Reason of discrepancy between Number analyzed of each row and Overall Number of Participants Analyzed: The analysis was performed only in patients who have data at each week.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MT-7117 | Change in Physician Global Assessment From Baseline up to Week 52 | Change from BL at Week 16 | -1.6 score on a scale | Standard Deviation 1.9 |
| MT-7117 | Change in Physician Global Assessment From Baseline up to Week 52 | Change from BL at Week 26 | -1.6 score on a scale | Standard Deviation 2.1 |
| MT-7117 | Change in Physician Global Assessment From Baseline up to Week 52 | Change from BL at Week 39 | -2.1 score on a scale | Standard Deviation 2.5 |
| MT-7117 | Change in Physician Global Assessment From Baseline up to Week 52 | Change from BL at Week 52 | -2.0 score on a scale | Standard Deviation 2.9 |
| Placebo | Change in Physician Global Assessment From Baseline up to Week 52 | Change from BL at Week 52 | -1.7 score on a scale | Standard Deviation 2.2 |
| Placebo | Change in Physician Global Assessment From Baseline up to Week 52 | Change from BL at Week 16 | -1.7 score on a scale | Standard Deviation 1.8 |
| Placebo | Change in Physician Global Assessment From Baseline up to Week 52 | Change from BL at Week 39 | -2.2 score on a scale | Standard Deviation 2.3 |
| Placebo | Change in Physician Global Assessment From Baseline up to Week 52 | Change from BL at Week 26 | -1.7 score on a scale | Standard Deviation 2.1 |